WESTON, Florida — ZyVersa Therapeutics, Inc. (OTCQB: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, highlights key data from a recently published study, Lipidomics Unveils Critical Lipid Pathway Shifts in Alport Syndrome, designed to elucidate how disrupted lipid metabolism contributes to lipotoxicity and progressive kidney damage in AS. To contextualize the lipidomic alterations observed in AS, a comparator group of patients with diabetic kidney disease (DKD) was included since lipotoxicity in this population has been extensively characterized and recognized as a central driver of podocyte injury and chronic kidney damage.
The researchers found that although both AS and DKD share lipotoxicity as a core mechanism, there were some distinct lipid alterations in AS when compared with DKD reflecting differences in metabolic pathways. AS demonstrated more pronounced changes in the lipid classes evaluated, indicating increased cellular stress. Lipid alterations in both AS and DKD were intricately linked to impaired ABCA1 lipid transport out of kidney cells (efflux) and the underlying renal injury processes of lipotoxicity, inflammation, and mitochondrial dysfunction. The study concluded that drugs that mediate renal lipid efflux to attenuate lipotoxicity have potential to mitigate renal disease progression.
“The relationship between lipotoxicity and kidney damage has been well established in chronic kidney diseases including AS, FSGS, and DKD. The authors of this paper expanded on this by identifying the specific lipid alterations that contribute to the lipotoxicity and kidney damage in in AS in comparison to lipid alterations in DKD,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO, and President. “Their data reinforce that impaired efflux of cholesterol and other lipids are key contributors to renal lipotoxicity, and the need for drug therapies, such as Cholesterol Efflux Mediator™ VAR 200, to restore lipid homeostasis and preserve kidney function. Currently, over 130,000 patients with kidney disease progress to renal failure each year in the US, and more than 800,000 patients are living with renal failure requiring dialysis or transplant to sustain life. We are hopeful that attenuating lipotoxicity with Cholesterol Efflux Mediator™ VAR 200 can help to reduce these statistics and improve patients’ quality of life. We are looking forward to the preliminary results from our Phase 2a VAR 200 clinical trial in patients with DKD around year’s end.”
ABOUT ZYVERSA THERAPEUTICS, INC.
ZyVersa (OTCQB: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of various kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases. FSGS is the lead indication for VAR 200, and obesity with cardiometabolic comorbidities is the lead indication for IC 100. For more information, please visit www.zyversa.com.
Corporate, IR, and Media Contact
Karen Cashmere
Chief Commercial Officer
[email protected]
786-251-9641